KR20080098382A - Ｉｌ-4 및/또는 ｉｌ-13에 결합하는 리간드 - Google Patents

Ｉｌ-4 및/또는 ｉｌ-13에 결합하는 리간드 Download PDF

Info

Publication number
KR20080098382A
KR20080098382A KR1020087020811A KR20087020811A KR20080098382A KR 20080098382 A KR20080098382 A KR 20080098382A KR 1020087020811 A KR1020087020811 A KR 1020087020811A KR 20087020811 A KR20087020811 A KR 20087020811A KR 20080098382 A KR20080098382 A KR 20080098382A
Authority
KR
South Korea
Prior art keywords
seq
dom10
dom9
ligand
single variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087020811A
Other languages
English (en)
Korean (ko)
Inventor
이안 톰린슨
아드리안 알라트 스투프
아민 세프
이누샤 드 실바
캐롤라인 제이. 디메치
말고르자타 푸페카
루돌프 엠. 티. 드 윌트
필립 디. 드류
스티브 홀름스
Original Assignee
도만티스 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 도만티스 리미티드 filed Critical 도만티스 리미티드
Publication of KR20080098382A publication Critical patent/KR20080098382A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/247—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020087020811A 2006-01-24 2007-01-24 Ｉｌ-4 및/또는 ｉｌ-13에 결합하는 리간드 Ceased KR20080098382A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76170806P 2006-01-24 2006-01-24
US60/761,708 2006-01-24

Publications (1)

Publication Number Publication Date
KR20080098382A true KR20080098382A (ko) 2008-11-07

Family

ID=38028503

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087020811A Ceased KR20080098382A (ko) 2006-01-24 2007-01-24 Ｉｌ-4 및/또는 ｉｌ-13에 결합하는 리간드

Country Status (16)

Country Link
US (3) US20110159003A1 (https=)
EP (1) EP1976882A2 (https=)
JP (2) JP2009523460A (https=)
KR (1) KR20080098382A (https=)
CN (1) CN101578298A (https=)
AU (1) AU2007209202A1 (https=)
BR (1) BRPI0710572A2 (https=)
CA (1) CA2636854A1 (https=)
CR (1) CR10179A (https=)
EA (1) EA200801515A1 (https=)
IL (1) IL192572A0 (https=)
MA (1) MA30175B1 (https=)
NO (1) NO20082942L (https=)
TW (2) TW200740843A (https=)
WO (1) WO2007085815A2 (https=)
ZA (1) ZA200806202B (https=)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2421464C2 (ru) 2005-10-21 2011-06-20 Новартис Аг Человеческие антитела к il-13 и их терапевтическое применение
WO2009138413A1 (en) * 2008-05-15 2009-11-19 Domantis Limited Single domain antibodies that bind il-13
JP2009536527A (ja) * 2006-05-09 2009-10-15 ジェネンテック・インコーポレーテッド 最適化されたスキャフォールドを備えた結合ポリペプチド
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
EP2195342A1 (en) * 2007-09-07 2010-06-16 Ablynx N.V. Binding molecules with multiple binding sites, compositions comprising the same and uses thereof
EP2036980A1 (de) * 2007-09-14 2009-03-18 Gruber, Jens Herabregulation der Genexpression mittels Nukleinsäure-beladener virusähnlicher Partikel
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
AU2017201007B2 (en) * 2007-10-15 2018-12-13 Sanofi Antibodies that bind IL-4 and/or IL-13 and their uses
CN102131827A (zh) * 2007-12-13 2011-07-20 葛兰素集团有限公司 用于肺部传递给药的组合物
WO2009089295A2 (en) 2008-01-07 2009-07-16 Government Of The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services Anti-hiv domain antibodies and method of making and using same
EP2631302A3 (en) * 2008-03-31 2014-01-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
EP2268668A1 (en) 2008-04-17 2011-01-05 Ablynx N.V. Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
HRP20170374T1 (hr) * 2008-09-26 2017-05-05 Ucb Biopharma Sprl Biološki proizvodi
BRPI0919714A2 (pt) * 2008-10-21 2015-12-08 Domantis Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, ácido nucleico, vetor, célula hospedeira, e, método para produzir um polipeptídeo
BRPI0919881B1 (pt) 2008-10-31 2021-09-08 Centocor Ortho Biotech Inc Proteína de arcabouço e seu método de geração, biblioteca e seu método de construção, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, composição, dispositivo médico e artigo de fabricação
AU2008364461A1 (en) * 2008-11-26 2010-06-03 Domantis Limited Ligands that bind IL-13
US8858940B2 (en) 2008-12-10 2014-10-14 Ablynx N.V. Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
US9394374B2 (en) 2009-05-28 2016-07-19 Glaxo Group Limited Antigen-binding proteins
EP2435481A1 (en) * 2009-05-28 2012-04-04 Glaxo Group Limited Il-13 binding protein
JP2012532620A (ja) * 2009-07-16 2012-12-20 グラクソ グループ リミテッド 改良型抗血清アルブミン結合単一可変ドメイン
BR112012001977A2 (pt) * 2009-07-29 2017-01-31 Glaxo Group Ltd domínio variável único de imunoglobulina, polipeptídeo isolado, ligante, proteína de fusão, ácido nucleico isolado, molécula de ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um polipeptídeo e para tratar e/ou prevenir uma condição, composição farmacêutica, uso de um domínio variável único, e, dispositivo de dispensação pulmonar.
CN102781959A (zh) 2010-02-05 2012-11-14 埃博灵克斯股份有限公司 能够结合血清白蛋白的肽和包含所述肽的化合物、构建体和多肽
PT3501499T (pt) * 2010-02-11 2022-11-22 Ablynx Nv Métodos e composições para a preparação de aerossóis
EP3569256B1 (en) 2010-04-30 2022-06-15 Janssen Biotech, Inc. Stabilized fibronectin domain compositions, methods and uses
JP6062375B2 (ja) 2011-01-06 2017-01-18 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｔｇｆ−ベータ受容体ｉｉに結合するリガンド
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
US9527925B2 (en) 2011-04-01 2016-12-27 Boehringer Ingelheim International Gmbh Bispecific binding molecules binding to VEGF and ANG2
BR112013026828A2 (pt) 2011-04-21 2016-11-29 Bristol Myers Squibb Co polipeptídeos de anticorpo que antagonizam cd40
EP2761066B1 (en) 2011-09-27 2018-12-05 Janssen Biotech, Inc. Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces
US10481164B2 (en) * 2012-03-26 2019-11-19 Amgen Inc. Method for using light scattering in real time to directly monitor and control impurity removal in purification processes
MX2014016038A (es) 2012-06-22 2015-08-14 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti - jagged 1 / jagged 2, anticuerpos anti - jagged activables y metodos para uso de los mismos.
JP6306588B2 (ja) 2012-08-21 2018-04-04 サノフィ・バイオテクノロジー Ｉｌ−４ｒアンタゴニストを投与することにより喘息を処置又は予防するための方法
EP3165535B1 (en) * 2012-08-22 2019-05-15 Mogam Biotechnology Research Institute Screening and engineering method of super-stable immunoglobulin variable domains and their uses
EP3828203B1 (en) * 2013-12-17 2024-04-24 MHS Care - Innovation LLC Compositions and methods for treating fatty tissue buildup
US11066467B2 (en) 2013-12-17 2021-07-20 Mhs Care-Innovation Llc Compositions and methods for treating ischemic heart disease
IL315136A (en) * 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
EP3129497B1 (en) * 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
PL3204095T3 (pl) 2014-10-10 2019-10-31 Ablynx Nv Urządzenie do inhalacji do stosowania w terapii aerozolowej chorób układu oddechowego
RU2017115670A (ru) 2014-10-10 2018-11-15 Аблинкс Н.В. Лечение инфекции рсв
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
CA3022697A1 (en) 2016-05-02 2017-11-09 Ablynx Nv Treatment of rsv infection
JP6293829B2 (ja) * 2016-08-05 2018-03-14 モガム インスティチュート フォー バイオメディカル リサーチＭＯＧＡＭ Ｉｎｓｔｉｔｕｔｅ ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ 安定化された免疫グロブリン可変ドメイン選別方法及び選別されたドメインの応用
WO2018099968A1 (en) 2016-11-29 2018-06-07 Ablynx N.V. Treatment of infection by respiratory syncytial virus (rsv)
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
US10611823B2 (en) 2016-12-14 2020-04-07 Hanssen Biotech, Inc CD137 binding fibronectin type III domains
NZ754187A (en) 2016-12-14 2026-02-27 Janssen Biotech Inc Cd8a-binding fibronectin type iii domains
KR102694419B1 (ko) 2017-10-30 2024-08-09 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CN108855003B (zh) * 2018-06-28 2021-01-05 南开大学 一种用于清除血液中炎性因子的免疫吸附剂及其制备方法
CN110746507B (zh) 2018-12-25 2020-06-26 江苏荃信生物医药有限公司 抗人白介素4受体α单克隆抗体及其应用
CN114126646B (zh) * 2019-02-27 2025-05-30 浙江纳米抗体技术中心有限公司 基于序列的高通量方法产生骆驼抗体以高分辨率覆盖广泛表位
WO2021011614A1 (en) 2019-07-16 2021-01-21 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4r antagonist
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
CN114786682B (zh) 2019-10-14 2024-07-16 Aro生物疗法公司 结合cd71的纤维粘连蛋白iii型结构域
WO2021076543A1 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Epcam binding fibronectin type iii domains
JP2023523600A (ja) 2020-04-22 2023-06-06 マブウェル （シャンハイ） バイオサイエンス カンパニー リミテッド ヒトプログラム細胞死リガンド１（ｐｄ－ｌ１）を標的とする単一可変ドメイン抗体およびその誘導体
KR20230008157A (ko) * 2020-05-06 2023-01-13 드래곤플라이 쎄라퓨틱스, 인크. 항체 표적화 clec12a 및 이의 사용
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
BR112023021318A2 (pt) 2021-04-14 2023-12-19 Aro Biotherapeutics Company Conjugados de domínio fn3-sirna e usos dos mesmos
CA3214552A1 (en) 2021-04-14 2022-10-20 Russell C. Addis Cd71 binding fibronectin type iii domains
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
EP4573119A1 (en) * 2022-08-17 2025-06-25 Institut National de la Santé et de la Recherche Médicale Improved anti-albumin nanobodies and their uses
JP7668943B2 (ja) * 2023-08-30 2025-04-25 ファイザー・インク 多重特異性抗体およびその使用
JP2025036273A (ja) * 2023-08-30 2025-03-14 ファイザー・インク 多重特異性抗体およびその使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869620A (en) * 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5637481A (en) * 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
ATE171472T1 (de) * 1992-02-19 1998-10-15 Schering Corp Klonierung und expression von humanisierten monoklonalen antikörpern gegen menschliches interleukin-4
US5596072A (en) * 1992-08-21 1997-01-21 Schering Corporation Method of refolding human IL-13
US7585847B2 (en) * 2000-02-03 2009-09-08 Coley Pharmaceutical Group, Inc. Immunostimulatory nucleic acids for the treatment of asthma and allergy
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.
AU2003290330A1 (en) * 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
GB0407315D0 (en) * 2003-07-15 2004-05-05 Cambridge Antibody Tech Human antibody molecules
SG10201404273QA (en) * 2003-12-23 2014-10-30 Genentech Inc Novel anti-il 13 antibodies and uses thereof
AU2005219837A1 (en) * 2004-02-27 2005-09-15 Regeneron Pharmaceuticals, Inc. IL-4/IL-13 sepecific polypetides and therapeutic uses thereof
AR049390A1 (es) * 2004-06-09 2006-07-26 Wyeth Corp Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI307630B (en) * 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
US7569586B2 (en) * 2004-08-16 2009-08-04 Theravance, Inc. Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity

Also Published As

Publication number Publication date
ZA200806202B (en) 2009-11-25
JP2009523460A (ja) 2009-06-25
EA200801515A1 (ru) 2009-02-27
BRPI0710572A2 (pt) 2013-01-08
TW200804593A (en) 2008-01-16
US20090060916A1 (en) 2009-03-05
MA30175B1 (fr) 2009-01-02
CR10179A (es) 2008-10-29
CA2636854A1 (en) 2007-08-02
AU2007209202A1 (en) 2007-08-02
WO2007085815A2 (en) 2007-08-02
US20110159003A1 (en) 2011-06-30
TW200740843A (en) 2007-11-01
US20120093830A1 (en) 2012-04-19
JP2009523459A (ja) 2009-06-25
CN101578298A (zh) 2009-11-11
EP1976882A2 (en) 2008-10-08
WO2007085815A3 (en) 2007-11-15
WO2007085815A8 (en) 2008-07-31
IL192572A0 (en) 2009-02-11
NO20082942L (no) 2008-10-15

Similar Documents

Publication Publication Date Title
KR20080098382A (ko) Ｉｌ-4 및/또는 ｉｌ-13에 결합하는 리간드
AU2020200981B2 (en) Multispecific antibodies, multispecific activatable antibodies and methods of using the same
JP2023109927A (ja) ヒトのがんを治療するための特異的抗ｃｄ３８抗体
KR101205643B1 (ko) 염증 질환을 치료하기 위한 조성물과 방법
KR20080090507A (ko) Ｖｅｇｆ 및/또는 ｅｇｆｒ에 대해 결합 특이성이 있는 리간드 및 그의 사용 방법
KR20080090414A (ko) 세포 표면 표적에 대한 결합 특이성이 있는 이중 특이성리간드 및 이의 사용방법
KR20080077261A (ko) Ｅｇｆｒ 및/또는 ｖｅｇｆ에 대해 결합 특이성이 있는리간드 및 그의 사용 방법
US20150087813A1 (en) Ligand
PT2321352E (pt) Composições monovalentes para ligação a cd28 e métodos de utilização
JP2019503167A (ja) Ｃｄ３８に対する抗原結合性ポリペプチド
JP2016540826A (ja) 抗ｅｆｎａ４抗体−薬物コンジュゲート
US11377504B2 (en) Antibody beneficial for treatment of solid tumors, antibody-drug conjugate, and cancer drug including same
JP2026510808A (ja) ヒト抗体を標的とするメラノーマとその治療方法
US20110223168A1 (en) Ligand that has binding specificity for il-4 and/or il-13
RU2815683C2 (ru) Мультспецифические антитела, мультспецифические активируемые антитела и способы их применения
WO2025099434A1 (en) Bcma binding molecules
MX2008009528A (en) Ligands that bind il-4 and/or il-13
MX2008007369A (en) Bispecific ligands with binding specificity to cell surface targets and methods of use therefor

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080825

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120120

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130822

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20131028

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130822

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I